

Elenco Poster
ID Title
Bacterial and fungal infections in immunocompromised host

10	P 1	A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center	Arturo Ciccullo, Roma
45	P 2	Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report	Alfredo Franco, Napoli
53	P 3	Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center	Giorgio Bozzi, Milano
111	P 4	Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery	Fabio Bulla, Catanzaro
156	P 5	A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment	Marianna Rossi, Monza

Basics in viral hepatitis

288	P 6	Comparison of immunoassays for quantitative serum HBsAg	Greta Roncarati, Bologna
330	P 7	Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay	Romina Salpini, Roma

Cancers in HIV

32	P 8	The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people	Laura Del Bono, Pisa
49	P 9	Non-AIDS-defining cancers in a cohort of HIV positive patients	Valentina Barocci, Ancona
116	P 10	Case report on oncopathology in HIV-infected patients	Zulfiya Akhmedjanova, Tashkent, Uzbekistan
145	P 11	Primitive NHL of bone in an HIV patient: case-report and review of literature	Alberto Amedeo, Bologna
253	P 12	Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study	Francesco Vadini, Pescara
261	P 13	Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster?	Erica Bacca, Modena
320	P 14	Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients	Stefano Verdenelli, Pisa
351	P 15	HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV	Giacomo Ciusa, Modena
358	P 16	Epidemiological analysis from a newly established anal HPV screening ambulatory	Marco Ridolfi, Roma

Gender issues

139	P 17	Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda	Giulia Micheli, Roma
204	P 18	Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study	Giulio Maria Corbelli, Roma
225	P 19	Transgender people and HIV	Michele Formisano, Taranto
232	P 20	HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study	Filippo Lagi, Firenze
365	P 21	HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART	Anna Carraro, Padova

HCV elimination

6	P 22	Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication	Maria Mazzitelli, Catanzaro
37	P 23	A fast track city micro-project to eradicate HCV infection in PLWHIV	Franco Maggiolo, Bergamo
43	P 24	A pilot intervention for HCV elimination among MSM in Rome: preliminary results	Pierluca Piselli, Roma
58	P 25	HCV eradication in people living with HIV in Sassari: the final countdown?	Andrea De Vito, Sassari
69	P 26	Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation	Paola Columpsi, Monza
83	P 27	Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer	Vincenzo Bianco, Napoli

Elenco Poster

ID	Title	
100 P 28	How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users	Alessandro Soria, Monza
124 P 29	Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD)	Mariantonietta Pisaturo, Napoli
132 P 30	Short course therapy for chronic hepatitis C infection	Giacomo Stroffolini, Torino
133 P 31	DAA failure in HCV genotype 3: virological features and efficacy of re-treatment	Mariantonietta Pisaturo, Napoli
186 P 32	Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome	Silvia Rosati, Roma
212 P 33	Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis	Luca Foroghi Biland, Roma
244 P 34	Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk	Giuseppe Greco, Napoli
285 P 35	Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases	Cinzia Caudai, Siena
313 P 36	Feasibility and impact of HCV treatment in a HRS in Milan	Guglielmo Arzilli, Milano
338 P 37	An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan	Sara Mazzilli, Milano
350 P 38	Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment	Blerta Kertusha, Roma
353 P 39	EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy	Paola Zuccalà, Latina
354 P 40	Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection	Biagio Pinchera, Napoli
357 P 41	HCV treatment in PWID: a linkage to care model in Cagliari	Luchino Chessa, Monserrato CA
Hepatitis epidemiology		
142 P 42	Hepatitis A: has the outbreak ended?	Elena Garlatti Costa, Pordenone
193 P 43	Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort	Laura Ambra Nicolini, Genova
215 P 44	HEV in Southern Italy. Still a chimera?	Chiara Dell'Isola, Napoli
243 P 45	Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals	Veronica Valastro, Napoli
HIV and COVID		
374 P 46	Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy	Leonardo Calza, Bologna
377 P 47	A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection	Elena Garlatti Costa, Pordenone
380 P 48	SARS-CoV-2 infection in a highly-experienced person living with HIV	Arturo Ciccullo, Roma
381 P 49	SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report	Gregorio Egidio Recchia, Roma
386 P 50	COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome	Annalisa Mondì, Roma
388 P 51	Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy	Andrea Mastrangelo, Milano
389 P 52	Management of emergency COVID-19 in prison, Monza experience	Valentina Costa, Monza
391 P 53	Psychological impact and awareness of COVID-19 in young people with HIV	Elena Mozzo, Padova
393 P 54	Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor?	Elena Garlatti Costa, Pordenone
395 P 55	Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients	Stefania Bernardi, Roma
HIV and nervous system		
140 P 56	Study of the types of the nervous system based on temperaments of HIV-infected patients	Zulfiya Akhmedjanova, Tashkent, Uzbekistan
141 P 57	Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression	Mattia Trunfio, Torino
173 P 58	Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV	Valentina Delle Donne, Roma
178 P 59	Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients	Valentina Delle Donne, Roma

Elenco Poster

ID	Title	
260 P 60	Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab	Camilla Muccini, Milano
265 P 61	In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition	Ilenia Pati, Bari
286 P 62	Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study	Anna Clelia Brita, Roma
302 P 63	Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV	Mattia Trunfio, Torino
304 P 64	Cryptococcal meningitis in a young woman HIV late presenter: a case report	Valentina Fortunato, Salerno
HIV cure		
183 P 65	A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naïve patients: background and preliminary data of a pilot project of the GLAD group	Gian Carlo Orofino, Torino
329 P 66	Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir+Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks	Samuele Gardin, Padova
336 P 67	Complementary-alternative medicines and self prescribed drugs use in women living with HIV	Lolita Sasset, Padova
HIV epidemiology and retention in care		
44 P 68	Availability of rapid HIV self-test in Italian pharmacies: a survey	Pierluca Piselli, Roma
72 P 69	REducing LAte Presenters Patients rate in Milan area (RELAPP Study): preliminary results	Marzia Bonfanti, Castellanza VA
81 P 70	May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience	Chiara Picarelli, Roma
87 P 71	High rates of lost-to-follow-up among naïve HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19	Viviana Rizzo, Napoli
149 P 72	Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital	Cristina Rovelli, Varese
157 P 73	Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population?	Francesco Maria Fusco, Napoli
196 P 74	The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients	Giulia Piazza, Bologna
205 P 75	Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019	Rossana Scutari, Roma
224 P 76	"EXTERNA": QoL Perception in PLWHIV during ID checkup	Antonella Antonino, Milano
233 P 77	HIV screening in migrant population living in "ghetti" in Apulia	Rossana Lattanzio, Bari
254 P 78	Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System	Assunta Navarra, Roma
274 P 79	Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection	Benedetta Fumarola, Brescia
305 P 80	HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey	Laura A. R. Rancilio, Milano
333 P 81	Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova	Eugenia Di Meo, Padova
359 P 82	Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival	Federica Cosentino, Catania
371 P 83	New diagnoses of HIV infection: what has changed in 10 years	Alessandra Tartaglia, Foggia
HIV immunology and immune-based therapies		
91 P 84	Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients	Marta Camici, Roma
240 P 85	Influence of HLA haplotype on immunological recovery in HIV-infected patients	Deborah Fiordelisi, Bari
HIV pathogenesis		
366 P 86	Oxidative Stress and gut microbiota composition in primary HIV infection	Stefania Cannizzo, Milano
HIV prevention (PrEP and PEP)		
4 P 87	PrEP awareness and attitudes in a survey among Italian clinicians	Arturo Ciccullo, Roma

Elenco Poster

ID	Title	
14	P 88 PrEP: the stories about who used the therapy	Marinella Zetti, Milano
21	P 89 Young People Inform Young People - Speak to the students with the Peer Section of the School Project	Rosario Galipò, Roma
46	P 90 Problems and difficulties in the management of a PrEP clinic	Alfredo Franco, Napoli
52	P 91 Post-exposure prophylaxis in real life	Alberto Venturelli, Piacenza
146	P 92 Determinants of drug start, schedule change and discontinuation in PrEP users	Roberto Rossotti, Milano
147	P 93 No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex	Roberto Rossotti, Milano
159	P 94 PreP: psychological and emotional aspects	Massimo Cernuschi, Milano
168	P 95 PrEP use amongst MSM in Italy: data from the EMIS 2017 survey	Maria Luisa Cosmaro, Milano
181	P 96 Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M. Annunziata Hospital, Florence	Elena Salomoni, Firenze
239	P 97 In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide	Martina Tamburello, Bologna
HIV virology		
158	P 98 Undetectable versus low level HIV viremia on patients taking antiretroviral therapy	Marco Nofri, Perugia
169	P 99 Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients	Laura Di Sante, Ancona
174	P 100 HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection	Giacomo Maria Butta, Milano
184	P 101 New potential anti-HIV agents: the antimicrobial peptide Temporin L	Annalisa Chianese, Napoli
194	P 102 Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients	Anna Casabianca, Fano PU
273	P 103 HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test	Tiziano Alice, Torino
315	P 104 Influence of HIV-1 V2 domain characteristics on immunological recovery under ART	Flavia Balena, Bari
318	P 105 Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates	Alessia Giannini, Siena
319	P 106 Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry	Francesco Saladini, Siena
325	P 107 In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations	Federica Giammarino, Siena
332	P 108 Does HLA-C binding stability affect HIV-1 infection?	Simona Mutascio, Verona
373	P 109 Genotypic Resistance test in rapid ART era	Marianna Rizzo, Foggia
HIV-associated tuberculosis		
210	P 110 Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV	Fabio Bulla, Catanzaro
Issues on antiretroviral therapy		
9	P 111 Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients	Massimiliano Lanzafame, Verona
89	P 112 Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis	Arturo Ciccullo, Roma
102	P 113 HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy	Francesca Lombardi, Roma
115	P 114 Side effects detected in HIV-positive patients depending on the ART regimen	Zulfiya Akhmedjanova, Tashkent, Uzbekistan
118	P 115 Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection	Vania Giacomet, Milano
129	P 116 A rare case of acute tubular necrosis tenofovir alafenamide-related	Michela Pontolillo, Chieti
152	P 117 New cases of diabetes dolutegravir-associated in HIV patients: a case series	Viola Cogliandro, Monza
170	P 118 Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART	Stefania Cannizzo, Milano
195	P 119 Viral outcome on tailored treatment strategy using cost saving antiretroviral (ARV)	Dario Bartolozzi, Firenze
200	P 120 The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study	Giulio Maria Corbelli, Roma
214	P 121 Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors-based regimens	Martina Ranzenigo, Milano

Elenco Poster

ID	Title	
220 P 122	Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice	Gabriele Fabbri, Ravenna
222 P 123	Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life	Francesco Paciosi, Perugia
245 P 124	Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV	Martina Spaziante, Roma
258 P 125	An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)	Marta Camici, Roma
284 P 126	Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype	Alberto Borghetti, Roma
289 P 127	Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients	Gianmarco Tagliaferri, Milano
301 P 128	Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center	Arianna Emiliozzi, Siena
314 P 129	Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients	Vittoria Moscatt, Catania
323 P 130	Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy	Anna Maria Spera, Salerno
337 P 131	Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir	Manuela Ceccarelli, Catania
339 P 132	Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection	Zeno Adrien Igor Pasquini, Bologna
361 P 133	Evaluation of lipid profile in HIV naïve patients, treated by TAF-based regimens	Salvatore Martini, Napoli
Management and treatment of viral hepatitis		
23 P 134	Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure	Ubaldo Visco Comandini, Roma
48 P 135	Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study	Viola Guardigni, Bologna
73 P 136	DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment	Laura Occhiello, Napoli
78 P 137	Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy	Carmine Minichini, Napoli
94 P 138	Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona	Valentina Iencinella, Ancona
218 P 139	Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bicitegravir/emtricitabine/tenofovir alafenamide	Marco Iannetta, Roma
363 P 140	Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy	Antonio Mastroianni, Cosenza
364 P 141	Current management of hepatitis B in sclerosis patients treated with disease-modify therapies	Patrizia Pasculli, Roma
Management of HIV infection		
11 P 142	Effect of 12-week physical activity program on sarcopenia measures in people living with HIV	Matteo Bonato, Milano
85 P 143	Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study	Daniela Mancusi, Cologno Monzese MI
135 P 144	HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays	Enrica Omiccioli, Cartoceto, Fano PL
227 P 145	Intestinal Alkaline Phosphatase levels in HIV infected patients	Flavia D'Andrea, Messina
321 P 146	Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer	Eugenio Nelson Cavallari, Roma
372 P 147	Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report	Irene Francesca Bottalico, Foggia
Non infectious comorbidities in HIV		
3 P 148	3TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density	Arturo Ciccullo, Roma
8 P 149	HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities	Francesco Ferrara, Perugia

Elenco Poster

ID	Title	
15	P 150 Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy	Leonardo Calza, Bologna
50	P 151 Cardiovascular disease risk markers in a small cohort of HIV-infected patients switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir	Massimiliano Lanzafame, Verona
65	P 152 Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort	Nicola Squillace, Monza
101	P 153 Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART	Martina Properzi, Brescia
138	P 154 Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study)	Matteo Chiurlo, Milano
185	P 155 A structured smoking cessation intervention in a single centre in patients living with HIV	Erika Riguccini, Perugia
219	P 156 Physical activity levels in HIV+ cohort of Pavia	Serena Ludovisi, Pavia
247	P 157 Machine learning vs Knowledge based approach in health outcomes' prediction in HIV	Davide Ferrari, Modena
249	P 158 Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPPPO cohort)	Silvia Nozza, Milano
278	P 159 Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 mono-infected virologically suppressed patients	Valentina Borgo, Siena
290	P 160 Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study	Alessandro Di Filippo, Pavia
347	P 161 Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment	Paola Vitiello, Monza
367	P 162 Archi-Prevalent project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV	Salvatore Martini, Napoli
Pediatric, adolescent, maternal, fetal aspects		
201	P 163 Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy	Federica Briano, Genova
Pharmacology, pharmacogenomics and drug interactions		
123	P 164 Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd]azulene-2-carboxylic acid derivatives	Sergii Demchenko, Kyiv, Ukraine
136	P 165 Antiviral activity of 6-(4-methylbenzyl)-3-arylamino-4H-[1,2,4]triazin-5-one derivatives against yellow fever	Evhenii Novodvorkyi, Kyiv, Ukraine
360	P 166 Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient	Chiara Alcantarini, Torino
Social and behavioural science, marginalized groups, community aspects and community surveys		
7	P 167 A survey as a chance of education on U=U in Italian general population	Annalisa Perziano, Torino
12	P 168 Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE	Carmine Falanga, Milano
13	P 169 HIV prescriptive trend 2018 vs 2019 in a teaching hospital in Rome	Giorgia Gambarelli, Roma
24	P 170 HAARTisticamente An unusual fashion show	Angela Infante, Roma
33	P 171 "La prevenzione va in tournée" a social experiment and on the field experience on HIV/STIs and social integration	Simona Nasta, Castellammare del Golfo TP
34	P 172 Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience	Giorgia Fracca, Milano
41	P 173 HIV rapid testing outside healthcare facilities: diagnostic and educational tool	Paolo Meli, Bergamo
60	P 174 Changes in causes of death of people living with HIV in a large teaching hospital in Rome	Damiano Farinacci, Roma
70	P 175 The PLWH perception of long acting injectable therapy	Filippo von Schloesser, Roma
82	P 176 Cohort observational study and HIV brochure in a teaching hospital in Rome	Giorgia Gambarelli, Roma
105	P 177 HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations	Manuel Maffeo, Candida
108	P 178 Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project*	Laura Sighinolfi, Ferrara
110	P 179 School and HIV. Cognitive and Emotional aspects for effective communication	Massimo Cernuschi, Milano

Elenco Poster

ID	Title	
113 P 180	Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team	Giacomo Dessì, Cagliari
114 P 181	"TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U"	Valeria Belvisi, Latina
160 P 182	Test, condom and chems: how the habits of people in Milan change. A test experience in a premise	Massimo Cernuschi, Milano
167 P 183	Coming out surrealista	Angela Infante, Roma
207 P 184	App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus	Marco Pedretti, Milano
209 P 185	PrEP between desire and needing: 2020 update	Dario Pavia, Modena
237 P 186	Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point	Daniele Calzavara, Milano
242 P 187	Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV	Cesare Di Felicianantonio, Manchester UK
279 P 188	The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV synergy. Preliminary data analysis	Eugenia Balestri, Pisa
282 P 189	HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey	Maddalena Cordioli, Verona
294 P 190	Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus	Carmine Urciuoli, Napoli
297 P 191	Linkage to care in HIV: the point of view of people with recent diagnosis	Massimo Oldrini, Roma
303 P 192	AIDS and other sexually transmitted diseases: what do young people know? – a Cross Sectional Study	Lorenza Pisano, Padova
343 P 193	Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic	Giovanni Mule, Milano
348 P 194	SRHR Sensitization and Education activities from Medical Students	Erica Clemente, Milano
356 P 195	"Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna	Bianca Granozzi, Bologna
369 P 196	WE TEST - National community-based HIV prevention program	Robert Dartenuc, Bologna
Vaccines		
55 P 197	Anti-body response to pneumococcal vaccination in HIV patient after supplementation with probiotic	Michela Pontolillo, Chieti
144 P 198	Adherence to the influenza vaccination campaign: experience of a large clinical center	Davide Moschese, Roma
155 P 199	HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study	Roberto Rossotti, Milano
161 P 200	Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience	Chiara Resnati, Monza
180 P 201	Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey	Gian Carlo Orofino, Torino
190 P 202	Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix© in People Living with HIV	Maria Mazzitelli, Catanzaro
280 P 203	Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M. Annunziata Hospital, Florence	Elena Salomoni, Firenze